cardio.hypertensive-emergency.glucocorticoid-induced.v1PRODUCTION

cardio.hypertensive-emergency.glucocorticoid-induced.v1

Glucocorticoid-induced hypertensive crisis (severe HTN driven by high-dose prednisone >20 mg/d, methylprednisolone, or hydrocortisone via mineralocorticoid receptor activation, Na+ retention, RAAS upregulation, and vascular sensitization — fluorinated dexamethasone less implicated)

cardiologyacuteadult

Hard-required inputs

0 / 13

Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Glucocorticoid-induced HTN crisis = high-dose exogenous steroid (prednisone >20 mg/d, methylprednisolone, hydrocortisone) → mineralocorticoid receptor activation + Na+/water retention + K+ wasting + RAAS upregulation + vascular sensitization → severe HTN often with hypoK. Pharmacology pivot: IV nicardipine first-line for BP control + SPIRONOLACTONE 25-100 mg PO (or eplerenone if gynecomastia concern) to block the OFFENDING mineralocorticoid effect at the receptor + aggressive K/Mg replacement + reduce/convert steroid (switch to dexamethasone — minimal MR activity — when clinically possible) + treat the underlying disease with steroid-sparing alternatives. Route to parent engine for shared HTN-emergency arc; this dossier owns the steroid-specific pharmacology + cumulative-toxicity surveillance + steroid-sparing transition.

Inputs

Actions

Advance rule

Set

Advance when

glucocorticoid-induced etiology confirmed (med history + dose + duration + hypoK pattern)

Patient inputs (13)

age*demographic • CONTEXT

Older patients (>60) more vulnerable to steroid-induced HTN due to baseline RAAS + endothelial dysfunction; pediatric high-dose steroid courses (oncology, transplant, severe asthma) also at risk

glucocorticoid_med_history_and_indication*history • CONTEXT

not present

Confirms etiology: drug name (prednisone, methylprednisolone, hydrocortisone, dexamethasone, betamethasone), dose, duration, indication (asthma, IBD, RA, SLE, vasculitis, COPD exacerbation, transplant immunosuppression, malignancy chemo bundle, adrenal replacement); fluorinated steroids (dex/betamethasone) have lower mineralocorticoid potency — different management

concurrent_NSAID_or_other_BP_offenders*history • CONTEXT

NSAID + steroid synergistic Na+ retention; also screen sympathomimetics, OCPs, VEGF inhibitors, calcineurin inhibitors

potassium*lab • INITIAL_WORKUP

HypoK common from MR activation (steroid → MR → K+ wasting); hypoK <3.0 + HTN classic for mineralocorticoid excess; replace aggressively + spironolactone

magnesium*lab • INITIAL_WORKUP

HypoMg often coexists with hypoK; replace before K replacement effective

creatinine*lab • INITIAL_WORKUP

eGFR drives nicardipine + spironolactone dosing; baseline for renal injury (severe HTN can precipitate AKI)

glucose*lab • INITIAL_WORKUP

Steroid-induced hyperglycemia + insulin resistance — risk of HHS overlap especially with high cumulative steroid dose

ecg_12_lead*imaging • INITIAL_WORKUP

not present

LVH from chronic steroid HTN; arrhythmia from hypoK; demand ischemia from severe HTN

troponin*lab • INITIAL_WORKUP

Demand ischemia rule-out (Type 2 MI in elderly with CAD + severe HTN)

neurologic_exam*symptom • INITIAL_WORKUP

Severe HTN can cause hypertensive encephalopathy + ICH; focal deficit → STAT CT head

sbp*vital • RED_FLAGS

Defines crisis threshold ≥180; drives titration of nicardipine + spironolactone; steroid-induced HTN often resistant to standard agents alone (need MR-blockade)

dbp*vital • RED_FLAGS

Component of MAP; DBP >120 supports crisis criterion; volume overload often elevates SBP > DBP (wide pulse pressure)

heart_rate*vital • RED_FLAGS

Often normal or mildly elevated (volume + MR-driven HTN, not catecholamine-driven); reflex bradycardia possible with severe HTN

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement

informationallife_threateninghhs_overlap_from_steroid_induced_hyperglycemia
Glucose >600 + osmotic symptoms + AMS in patient on chronic high-dose steroid → HHS overlap from steroid-induced insulin resistance + hyperglycemia (cumulative steroid dose + DM2 risk factor synergy)
Trigger could not be auto-evaluated — needs clinician judgement.
informationallife_threateningopportunistic_infection_on_chronic_steroid
New fever + respiratory symptoms + CXR infiltrate in patient on prednisone >20 mg/d for >1 month → PCP, aspergillosis, CMV reactivation, atypical mycobacterial — opportunistic infection rule-out + early empiric coverage
Trigger could not be auto-evaluated — needs clinician judgement.
informationallife_threateningadrenal_insufficiency_from_rapid_taper_after_chronic_use
Hypotension paradox + abdominal pain + AMS + hypoglycemia in patient with rapid steroid taper after chronic >2 weeks use → iatrogenic adrenal insufficiency (HPA axis suppression + premature taper)
Trigger could not be auto-evaluated — needs clinician judgement.
informationallife_threateningsteroid_psychosis_with_suicide_risk
Acute mood/psychosis symptoms (mania, depression, hallucinations, paranoia, suicidal ideation) in patient on high-dose steroid (especially pulse methylprednisolone 500-1000 mg/d) → steroid-induced psychiatric crisis with suicide risk
Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold

Loading…

Recommended regimen

Glucocorticoid-induced HTN crisis — IV nicardipine first-line + SPIRONOLACTONE 25-100 mg PO (block offending MR effect) + aggressive K/Mg replacement + REDUCE/CONVERT steroid (switch to dexamethasone, lowest MR activity) + steroid-sparing transition (DMARDs/biologics) + prophylactic MR-blockade during chronic high-dose courses

axis: glucocorticoid_induced_htn_crisis_pharmacology

Selected axis "Glucocorticoid-induced HTN crisis — IV nicardipine first-line + SPIRONOLACTONE 25-100 mg PO (block offending MR effect) + aggressive K/Mg replacement + REDUCE/CONVERT steroid (switch to dexamethasone, lowest MR activity) + steroid-sparing transition (DMARDs/biologics) + prophylactic MR-blockade during chronic high-dose courses" by default fallback (first axis)

nicardipine
first line
dihydropyridine_ccb
5 mg/h IV → titrate by 2.5 mg/h q5-15 min (max 15 mg/h) to SBP <160 within 2 h • IV • continuous infusion
triggers: steroid_induced_HTN_crisis_confirmed
AHA 2025 HTN Class I — IV nicardipine first-line for non-aortic-dissection HTN crisis; preserves cerebral perfusion + titratable; safe in volume-overloaded steroid patients
rxcui 7396
spironolactone
first line
mineralocorticoid_receptor_antagonist
25-100 mg PO daily (load 100 mg PO once if severe; maintenance 25-50 mg PO daily); titrate per K + BP • PO • daily
triggers: steroid_induced_HTN_with_hypoK, glucocorticoid_induced_HTN_crisis
Funder NEJM 2003 PMID 14507948 + Williams JAMA 2018 PMID 30575491 — MR antagonist directly blocks the offending mineralocorticoid effect of high-dose glucocorticoid at the receptor level; pathophysiologically targeted therapy + corrects hypoK + addresses Na+ retention
rxcui 9997
eplerenone
first line
selective_mineralocorticoid_receptor_antagonist
25-50 mg PO BID (max 100 mg/d) • PO • BID
triggers: gynecomastia_concern_or_intolerance_to_spironolactone, CKD_with_close_K_monitoring
Selective MR antagonist without anti-androgen effects (no gynecomastia); slightly less potent than spironolactone but better tolerated long-term
rxcui 298869
labetalol
second line
mixed_alpha_beta_blocker
10-20 mg IV q10 min titrate (max 300 mg cumulative), OR infusion 0.5-2 mg/min • IV • PRN bolus or continuous
triggers: persistent_HTN_after_nicardipine_and_spironolactone
Mixed α/β safe in steroid-induced HTN (no unopposed-alpha concern); standard HTN-emergency adjunct per AHA 2025
rxcui 6185
furosemide
comorbidity specific
loop_diuretic
20-40 mg IV (cautious — combine with K replacement + spironolactone protection) • IV • q6-12h PRN
triggers: volume_overload_with_pulmonary_edema, severe_steroid_induced_Na_retention
Adjunct for volume overload; CAUTION — worsens hypoK alone; use only with concurrent K replacement + spironolactone to protect K
rxcui 4603
potassium chloride
first line
electrolyte
KCl 40 mEq PO TID OR 10-20 mEq IV/h (max 20 mEq/h peripheral, 40 mEq/h central) • PO + IV • as needed to target K 4-5
triggers: hypokalemia_K_below_3.5
Steroid-induced MR activation → K wasting → hypoK common; aggressive replacement essential before BP control fully effective
rxcui 8591
magnesium sulfate
first line
electrolyte
2-4 g IV (1-2 g/h infusion if severe) • IV • as needed to target Mg 2.0-2.5
triggers: hypomagnesemia_Mg_below_2.0
HypoMg coexists with hypoK; correct Mg first or K replacement ineffective; arrhythmia prevention
rxcui 6585
dexamethasone
comorbidity specific
fluorinated_glucocorticoid_low_MR_activity
0.75 mg = 5 mg prednisone equivalent (convert at equipotent dose) • PO/IV • per indication
triggers: need_to_continue_steroid_with_lower_MR_activity
Fluorinated steroid has MINIMAL mineralocorticoid receptor activity vs prednisone/methylprednisolone/hydrocortisone; switch when clinically possible to reduce MR-driven HTN + hypoK while maintaining glucocorticoid effect
rxcui 3264
hydrocortisone (stress-dose for adrenal insufficiency rescue)
comorbidity specific
glucocorticoid_replacement
100 mg IV bolus then 50-100 mg IV q6-8h × 24-48 h then slow taper • IV • q6-8h then taper
triggers: adrenal_insufficiency_from_rapid_steroid_taper_after_chronic_use, paradoxical_hypotension_in_chronic_steroid_user
Iatrogenic adrenal insufficiency from over-rapid taper after >2 weeks chronic use; stress-dose protocol per Endocrine Society 2016
rxcui 5492
STEROID-SPARING TRANSITION (DMARDs, biologics, calcineurin inhibitors)
add on
disease_modifying_immunosuppression
MTX 7.5-25 mg/wk + folic acid; OR hydroxychloroquine 200-400 mg/d; OR azathioprine 1-2.5 mg/kg/d; OR cyclosporine 2-5 mg/kg/d; OR biologics (rituximab, tocilizumab, TNFi per disease) • PO + IV • per regimen
triggers: ongoing_high_dose_steroid_with_steroid_sparing_eligible_disease
ACR 2017 PMID 28585410 — long-term goal is lowest effective steroid dose with steroid-sparing immunosuppression; specialty-led (rheum, ID, onc, transplant)
PROPHYLACTIC SPIRONOLACTONE during high-dose courses
add on
prevention_protocol
25-50 mg PO daily during prednisone >20 mg/d courses, especially planned >2 weeks • PO • daily
triggers: planned_high_dose_steroid_course_more_than_2_weeks
AACE 2024 + emerging consensus — prophylactic MR-blockade prevents steroid-induced HTN + hypoK in high-dose courses; consider routinely with prednisone >20 mg/d × ≥2 weeks
AVOID concurrent NSAIDs during steroid therapy
contraindication substitute
avoid_combination
AVOID • N/A • N/A
triggers: glucocorticoid_induced_HTN_crisis
NSAID + steroid synergistic Na+ retention + RAAS upregulation + GI bleed risk; substitute acetaminophen + topical NSAID + adjuvants for pain control
STEROID TAPER plan (gradual over 4-12 weeks if chronic >2 weeks use)
add on
prevention_protocol
Reduce by 5-10 mg/week if prednisone >40 mg, 2.5-5 mg/week if 20-40 mg, 1-2.5 mg/week if <20 mg; switch to alternate-day dosing in last phase • PO • graduated reduction
triggers: chronic_steroid_use_more_than_2_weeks_being_discontinued
Endocrine Society 2016 — gradual taper avoids adrenal insufficiency from HPA axis suppression; Synacthen test if uncertain about recovery
BONE PROTECTION: bisphosphonate + Ca + vit D + DEXA
add on
prevention_protocol
Alendronate 70 mg PO weekly OR zoledronate 5 mg IV annually + Ca 1200 mg/d + vit D 800-2000 IU/d; DEXA at baseline + q1-2 years • PO + IV • weekly/annually
triggers: steroid_more_than_5_mg_prednisone_equivalent_for_3_months
ACR 2017 PMID 28585410 — glucocorticoid-induced osteoporosis prevention in chronic users >5 mg prednisone for ≥3 months

outpatient playbook — drug actions (5)

1. continue spironolactone if continued steroid
rxcui 9997
25-50 mg PO daily • PO • daily
trigger: Continued steroid
Sustained MR blockade prophylaxis
2. continue PO antihypertensive regimen
rxcui 17767
Amlodipine + lisinopril ± chlorthalidone • PO • daily
trigger: Sustained HTN control
ACC/AHA 2025 4-tier ladder
3. continue lowest-effective steroid dose with steroid-sparing therapy
rxcui 8638
Prednisone <5 mg/d with MTX/HCQ/AZA/biologic OR off steroid if disease in remission • PO + SC + IV • per regimen
trigger: Long-term disease control
ACR 2017 — minimize cumulative steroid exposure
4. continue bone protection + PCP prophylaxis
Alendronate weekly + Ca/vit D + TMP-SMX daily if chronic high-dose • PO • weekly + daily
trigger: Chronic steroid
ACR 2017
5. glucose management for steroid-DM
rxcui 6809
Metformin + insulin per A1c • PO + SC • daily
trigger: Steroid-induced hyperglycemia
ADA 2026

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: High-dose glucocorticoid therapy (prednisone >20 mg/d, methylprednisolone IV, hydrocortisone replacement-plus, or stress-dose IV) with new SBP ≥180 / DBP ≥120 — chronic high-dose use commonly precipitates within 2-6 weeks (Fardet J Hypertens 2011); Recent IV pulse methylprednisolone (500-1000 mg/d for SLE flare, transplant rejection, MS flare, vasculitis) → acute BP spike within hours to days — high mineralocorticoid effect at pulse doses; High-dose glucocorticoid + concurrent NSAID (additive Na+ retention + RAAS) → severe HTN crisis with hypoK + edema; classic outpatient presentation.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Glucocorticoid-induced hypertensive crisis (severe HTN driven by high-dose prednisone >20 mg/d, methylprednisolone, or hydrocortisone via mineralocorticoid receptor activation, Na+ retention, RAAS upregulation, and vascular sensitization — fluorinated dexamethasone less implicated)** (cardio.hypertensive-emergency.glucocorticoid-induced.v1).
Scope: Glucocorticoid-induced HTN crisis = high-dose exogenous steroid (prednisone >20 mg/d, methylprednisolone, hydrocortisone) → mineralocorticoid receptor activation + Na+/water retention + K+ wasting + RAAS upregulation + vascular sensitization → severe HTN often with hypoK. Pharmacology pivot: IV nicardipine first-line for BP control + SPIRONOLACTONE 25-100 mg PO (or eplerenone if gynecomastia concern) to block the OFFENDING mineralocorticoid effect at the receptor + aggressive K/Mg replacement + reduce/convert steroid (switch to dexamethasone — minimal MR activity — when clinically possible) + treat the underlying disease with steroid-sparing alternatives. Route to parent engine for shared HTN-emergency arc; this dossier owns the steroid-specific pharmacology + cumulative-toxicity surveillance + steroid-sparing transition.

No severity triggers fired against current inputs.

Plan

Regimen axis: **Glucocorticoid-induced HTN crisis — IV nicardipine first-line + SPIRONOLACTONE 25-100 mg PO (block offending MR effect) + aggressive K/Mg replacement + REDUCE/CONVERT steroid (switch to dexamethasone, lowest MR activity) + steroid-sparing transition (DMARDs/biologics) + prophylactic MR-blockade during chronic high-dose courses**.
1. nicardipine 5 mg/h IV → titrate by 2.5 mg/h q5-15 min (max 15 mg/h) to SBP <160 within 2 h IV continuous infusion (dihydropyridine_ccb, first line) — AHA 2025 HTN Class I — IV nicardipine first-line for non-aortic-dissection HTN crisis; preserves cerebral perfusion + titratable; safe in volume-overloaded steroid patients
2. spironolactone 25-100 mg PO daily (load 100 mg PO once if severe; maintenance 25-50 mg PO daily); titrate per K + BP PO daily (mineralocorticoid_receptor_antagonist, first line) — Funder NEJM 2003 PMID 14507948 + Williams JAMA 2018 PMID 30575491 — MR antagonist directly blocks the offending mineralocorticoid effect of high-dose glucocorticoid at the receptor level; pathophysiologically targeted therapy + corrects hypoK + addresses Na+ retention
3. eplerenone 25-50 mg PO BID (max 100 mg/d) PO BID (selective_mineralocorticoid_receptor_antagonist, first line) — Selective MR antagonist without anti-androgen effects (no gynecomastia); slightly less potent than spironolactone but better tolerated long-term
4. labetalol 10-20 mg IV q10 min titrate (max 300 mg cumulative), OR infusion 0.5-2 mg/min IV PRN bolus or continuous (mixed_alpha_beta_blocker, second line) — Mixed α/β safe in steroid-induced HTN (no unopposed-alpha concern); standard HTN-emergency adjunct per AHA 2025
5. furosemide 20-40 mg IV (cautious — combine with K replacement + spironolactone protection) IV q6-12h PRN (loop_diuretic, comorbidity specific) — Adjunct for volume overload; CAUTION — worsens hypoK alone; use only with concurrent K replacement + spironolactone to protect K
6. potassium chloride KCl 40 mEq PO TID OR 10-20 mEq IV/h (max 20 mEq/h peripheral, 40 mEq/h central) PO + IV as needed to target K 4-5 (electrolyte, first line) — Steroid-induced MR activation → K wasting → hypoK common; aggressive replacement essential before BP control fully effective
7. magnesium sulfate 2-4 g IV (1-2 g/h infusion if severe) IV as needed to target Mg 2.0-2.5 (electrolyte, first line) — HypoMg coexists with hypoK; correct Mg first or K replacement ineffective; arrhythmia prevention
8. dexamethasone 0.75 mg = 5 mg prednisone equivalent (convert at equipotent dose) PO/IV per indication (fluorinated_glucocorticoid_low_MR_activity, comorbidity specific) — Fluorinated steroid has MINIMAL mineralocorticoid receptor activity vs prednisone/methylprednisolone/hydrocortisone; switch when clinically possible to reduce MR-driven HTN + hypoK while maintaining glucocorticoid effect
9. hydrocortisone (stress-dose for adrenal insufficiency rescue) 100 mg IV bolus then 50-100 mg IV q6-8h × 24-48 h then slow taper IV q6-8h then taper (glucocorticoid_replacement, comorbidity specific) — Iatrogenic adrenal insufficiency from over-rapid taper after >2 weeks chronic use; stress-dose protocol per Endocrine Society 2016
10. STEROID-SPARING TRANSITION (DMARDs, biologics, calcineurin inhibitors) MTX 7.5-25 mg/wk + folic acid; OR hydroxychloroquine 200-400 mg/d; OR azathioprine 1-2.5 mg/kg/d; OR cyclosporine 2-5 mg/kg/d; OR biologics (rituximab, tocilizumab, TNFi per disease) PO + IV per regimen (disease_modifying_immunosuppression, add on) — ACR 2017 PMID 28585410 — long-term goal is lowest effective steroid dose with steroid-sparing immunosuppression; specialty-led (rheum, ID, onc, transplant)
11. PROPHYLACTIC SPIRONOLACTONE during high-dose courses 25-50 mg PO daily during prednisone >20 mg/d courses, especially planned >2 weeks PO daily (prevention_protocol, add on) — AACE 2024 + emerging consensus — prophylactic MR-blockade prevents steroid-induced HTN + hypoK in high-dose courses; consider routinely with prednisone >20 mg/d × ≥2 weeks
12. AVOID concurrent NSAIDs during steroid therapy AVOID N/A N/A (avoid_combination, contraindication substitute) — NSAID + steroid synergistic Na+ retention + RAAS upregulation + GI bleed risk; substitute acetaminophen + topical NSAID + adjuvants for pain control
13. STEROID TAPER plan (gradual over 4-12 weeks if chronic >2 weeks use) Reduce by 5-10 mg/week if prednisone >40 mg, 2.5-5 mg/week if 20-40 mg, 1-2.5 mg/week if <20 mg; switch to alternate-day dosing in last phase PO graduated reduction (prevention_protocol, add on) — Endocrine Society 2016 — gradual taper avoids adrenal insufficiency from HPA axis suppression; Synacthen test if uncertain about recovery
14. BONE PROTECTION: bisphosphonate + Ca + vit D + DEXA Alendronate 70 mg PO weekly OR zoledronate 5 mg IV annually + Ca 1200 mg/d + vit D 800-2000 IU/d; DEXA at baseline + q1-2 years PO + IV weekly/annually (prevention_protocol, add on) — ACR 2017 PMID 28585410 — glucocorticoid-induced osteoporosis prevention in chronic users >5 mg prednisone for ≥3 months

Setting playbook (outpatient) — Long-term PCP + specialty (rheum/ID/endo/onc) coordination — sustained BP <130/80, lowest effective steroid dose with steroid-sparing therapy, comprehensive complication surveillance (bone, glucose, infection, mood, eye, cardiovascular), MedicAlert + stress-dose protocol for chronic steroid users
15. continue spironolactone if continued steroid 25-50 mg PO daily PO daily — Continued steroid (Sustained MR blockade prophylaxis)
16. continue PO antihypertensive regimen Amlodipine + lisinopril ± chlorthalidone PO daily — Sustained HTN control (ACC/AHA 2025 4-tier ladder)
17. continue lowest-effective steroid dose with steroid-sparing therapy Prednisone <5 mg/d with MTX/HCQ/AZA/biologic OR off steroid if disease in remission PO + SC + IV per regimen — Long-term disease control (ACR 2017 — minimize cumulative steroid exposure)
18. continue bone protection + PCP prophylaxis Alendronate weekly + Ca/vit D + TMP-SMX daily if chronic high-dose PO weekly + daily — Chronic steroid (ACR 2017)
19. glucose management for steroid-DM Metformin + insulin per A1c PO + SC daily — Steroid-induced hyperglycemia (ADA 2026)

Non-pharmacologic actions:
- 90-day fill auto-refill confirmed annually
- Medication card in wallet
- MedicAlert bracelet active for chronic steroid users (stress-dose protocol)
- Annual flu vaccine + age-appropriate vaccines (avoid live vaccines on >20 mg prednisone)
- Lifestyle counseling (DASH diet, exercise, sleep)

AVOID / contraindication checks:
- Simultaneous_NSAID_avoid_in_steroid_induced_HTN_crisis (additive Na+ retention + RAAS + GI bleed risk; AHA 2025; ACR 2017)
- Abrupt_steroid_cessation_avoid_after_chronic_use_more_than_2_weeks (adrenal insufficiency risk; Endocrine Society 2016)
- Spironolactone_caution_eGFR_below_30 (hyperK risk; reduce dose or use eplerenone with close K monitoring)
- Spironolactone_avoid_K_above_5.5 (hyperK contraindication)
- Fluorinated_steroid_dexamethasone_preferred_when_continued_steroid_needed_with_HTN (lowest MR activity)
- Loop_diuretic_with_K_replacement_and_spironolactone_protection_only (alone worsens hypoK)
- Prophylactic_spironolactone_during_high_dose_steroid_courses_planned_more_than_2_weeks (AACE 2024)
- Bone_protection_bisphosphonate_for_chronic_steroid_more_than_5_mg_prednisone_for_3_months (ACR 2017 PMID 28585410)
- PCP_prophylaxis_for_prednisone_more_than_20_mg_for_more_than_1_month_TMP SMX_or_atovaquone
- Avoid_live_vaccines_on_immunosuppressive_steroid_doses_more_than_20_mg_prednisone

Monitoring

Regimen monitoring:
- continuous ECG q15min BP minimum 24h (AHA 2025 HTN)
- q4-6h BMP Mg until normalized
- daily glucose for steroid DM screening
- daily weight for volume status
- serial neuro exam q2h x 12h for encephalopathy or ICH
- infection surveillance temp WBC CXR if respiratory symptoms (PCP, aspergillosis)
- adrenal insufficiency surveillance during taper (hypotension, hypoglycemia, AMS)
- psychiatric screening for steroid psychosis especially high dose pulse
- home BP log weekly during taper then monthly
- K check q1-2 weeks during steroid and spironolactone titration
- HbA1c q3 months for steroid DM
- DEXA baseline then q1-2 years for chronic users
- lipid panel q6-12 months
- ophthalmology annual for cataract glaucoma

Setting (outpatient) monitoring:
- Quarterly BP
- Annual ECG + lipid + A1c + ophthalmology
- q1-2 year DEXA
- Annual medication review + adherence verification

Follow-up plan: STEROID MINIMIZATION: confirmed plan to taper to lowest effective dose (or off) over 4-12 weeks per indication + disease control; STEROID-SPARING TRANSITION: rheum/ID/onc-led DMARD/biologic/calcineurin-inhibitor introduction with overlap (MTX, hydroxychloroquine, azathioprine, cyclosporine, biologics like rituximab/tocilizumab/TNFi); PROPHYLACTIC SPIRONOLACTONE 25-50 mg PO daily during ongoing high-dose courses; BP MONITORING: weekly home BP during steroid taper, monthly during chronic low-dose maintenance; K MONITORING: q1-2 weeks during steroid + spironolactone titration; STEROID-RELATED COMPLICATION SURVEILLANCE: bone density (DEXA + bisphosphonate prophylaxis if >5 mg prednisone equivalent for ≥3 months — ACR 2017 PMID 28585410), HbA1c (steroid-DM screening q3 months), lipid panel, ophthalmology (cataracts, glaucoma), PCP prophylaxis if >20 mg prednisone for ≥1 month (TMP-SMX or atovaquone), VZV reactivation surveillance, vaccination optimization (avoid live vaccines on >20 mg prednisone); ADRENAL AXIS RECOVERY: stress-dose protocol issued + medical-alert bracelet for chronic steroid users; PSYCHIATRIC follow-up if steroid psychosis history; PCP + endocrinology + relevant specialty (rheum/ID/onc) follow-up within 1-2 weeks
- Close-out criterion: steroid taper plan documented + steroid-sparing transition initiated + prophylactic spironolactone + bone protection + glucose monitoring + adrenal recovery plan + 1-2 wk follow-up booked

Monitoring phase: Continuous ECG + telemetry; q15-30 min BP; q4-6h BMP + Mg until normalized; daily glucose checks (steroid-DM); daily weight (volume status); serial neuro exam q2h × 12 h; UOP; infection surveillance (temp, WBC, CXR if respiratory symptoms)

Disposition

Current setting: outpatient — Long-term PCP + specialty (rheum/ID/endo/onc) coordination — sustained BP <130/80, lowest effective steroid dose with steroid-sparing therapy, comprehensive complication surveillance (bone, glucose, infection, mood, eye, cardiovascular), MedicAlert + stress-dose protocol for chronic steroid users

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + cardio.htn.resistant.v1 for chronic management; cross-link to endo.cushing_syndrome.v1 if endogenous Cushing diagnosed

Escalation triggers (move to higher acuity):
- Recurrent HTN crisis → urgent visit + reassess regimen
- New cushingoid features → endocrine consult + steroid review
- New osteoporotic fracture → orthopedics + bone protection escalation
- New steroid-DM not controlled → endocrinology
- Recurrent infections → ID + immunology

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Glucose >600 + osmotic symptoms + AMS in patient on chronic high-dose steroid → HHS overlap from steroid-induced insulin resistance + hyperglycemia (cumulative steroid dose + DM2 risk factor synergy)
- [LIFE_THREATENING] New fever + respiratory symptoms + CXR infiltrate in patient on prednisone >20 mg/d for >1 month → PCP, aspergillosis, CMV reactivation, atypical mycobacterial — opportunistic infection rule-out + early empiric coverage
- [LIFE_THREATENING] Hypotension paradox + abdominal pain + AMS + hypoglycemia in patient with rapid steroid taper after chronic >2 weeks use → iatrogenic adrenal insufficiency (HPA axis suppression + premature taper)

Citations

- 2025 ACC/AHA HTN Guideline (Whelton) + ACR 2017 GC use in rheumatic disease (Buckley PMID 28585410) + AACE 2024 glucocorticoid-induced metabolic complications consensus + Endocrine Society 2016 adrenal insufficiency [PMID:28585410](https://pubmed.ncbi.nlm.nih.gov/28585410/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 14507948) [PMID:14507948](https://pubmed.ncbi.nlm.nih.gov/14507948/)
- Cited evidence (PMID 30575491) [PMID:30575491](https://pubmed.ncbi.nlm.nih.gov/30575491/)
- Cited evidence (PMID 18334580) [PMID:18334580](https://pubmed.ncbi.nlm.nih.gov/18334580/)

Last reconciled with current guidelines: 2026-05-15.

References

2025 ACC/AHA HTN Guideline (Whelton) + ACR 2017 GC use in rheumatic disease (Buckley PMID 28585410) + AACE 2024 glucocorticoid-induced metabolic complications consensus + Endocrine Society 2016 adrenal insufficiency — PMID:28585410
Cited evidence (PMID 38613493) — PMID:38613493
Cited evidence (PMID 14507948) — PMID:14507948
Cited evidence (PMID 30575491) — PMID:30575491
Cited evidence (PMID 18334580) — PMID:18334580